Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Bupropion hydrochloride, an atypical antidepressant, is the first non-nicotine product that, in its sustained release form (bupropion SR), has been licensed as an aid for smoking cessation. The specialized literature on bupropion SR and smoking cessation is critically reviewed. The pharmacological profile, dosage and administration, contraindications, as well as the clinical efficacy, safety and tolerability data of bupropion are discussed. Recent reports suggest that its mode of actions might be different to what had originally been proposed. When prescribed appropriately, it appears to be a safe, well-tolerated and effective medication in combination with smoking cessation counselling--for a wide range of smokers, as shown in several multicentre double-blind, placebo-controlled clinical trials. Further research is needed on aspects such as the optimal duration of treatment, the potential role of combination therapy with NRT and psychological interventions, and to establish its effectiveness in smokers with other psychiatric disorders or when used with only minimal support by general practitioners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 5×
“nificantly more frequent with bupropion SR (300 mg dose) than with placebo were insomnia and dry mouth.(9,10) Data from clinical studies”
BackgroundMethodInfluentialEffects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073 · cited 1×
“This seems to play a crucial role.(4) It has been suggested that the development of withdrawal symptoms may be mediated by noradrenergic neurones in the”
BackgroundNicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Clinical Practice Guideline: Allergic Rhinitis
Seidman, M. D., Gurgel, R. K., Lin, S. Y., Schwartz, S. R., Baroody, F. M., Bonner, J. R., Dawson, D. E., Dykewicz, M. S., Hackell, J. M., Han, J. K., et al. (2015) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599814561600 · Cited by 671
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Nicotine delivery kinetics and abuse liability.
Henningfield, J. E., & Keenan, R. M. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.5.743 · Cited by 411 · cited 1×
“chronic use.(3) The positive reinforcement of nicotine may be a consequence of stimulation and desensitization of the heterogeneous popu-”
BackgroundHays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
The effect of bupropion on nicotine craving and withdrawal
Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., & DeVeaugh-Geiss, J. (2000) · Psychopharmacology · doi:10.1007/s002130050022 · Cited by 259
Dunner, D. L., Zisook, S., Billow, A. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0705 · Cited by 180 · cited 3×
“tive safety surveillance study of its use in the treatment of depression, as having occurred in patients with predisposing conditions.(34)”
BackgroundMethodBupropion for Smoking Cessation
Dale, L. C., Glover, E. D., Sachs, D. P. L., Schroeder, D. R., Offord, K. P., Croghan, I. T., & Hurt, R. D. (2001) · Chest · doi:10.1378/chest.119.5.1357 · Cited by 177
Cited by
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
How does bupropion work as a smoking cessation aid?
Warner, C., & Shoaib, M. (2005) · Addiction Biology · doi:10.1080/13556210500222670 · Cited by 115
“A review of its efficacy, safety and pharmacological profile has been published recently (Martinez-Raga et al., 2003).”
BackgroundMedication screening for smoking cessation: A proposal for new methodologies
Perkins, K. A., Stitzer, M., & Lerman, C. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0105-5 · Cited by 91
Metadata
- Authors
- MARTÍNEZ-RAGA, J., KEANEY, F., SUTHERLAND, G., PEREZ-GALVEZ, B., & STRANG, J.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 8
- Issue
- 1
- Pages
- 13-21
- ISSN
- 1355-6215 (ISSN-L)
- OpenAlex
- W2033837866
- Cited by
- 34
- References
- 11
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. https://app.cochat.ai/papers/10.1080/1355621031000069837
- The paper
- MARTÍNEZ-RAGA, J., KEANEY, F., SUTHERLAND, G., PEREZ-GALVEZ, B., & STRANG, J. (2003). Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addiction Biology. https://doi.org/10.1080/1355621031000069837
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.